AI-Powered Viz ICH Technology Cuts Transfer Time and Enhances Outcomes for Intracerebral Hemorrhage Patients

A New Study Shows AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes for Intracerebral Hemorrhage Patients SAN FRANCISCO—Viz.ai, a leading provider of AI-driven disease detection and care coordination, recently released new clinical data demonstrating the effectiveness of its Viz ICH and Viz ICH Plus technologies in optimizing the care of patients with intracerebral hemorrhage (ICH). The study, titled “Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,” underscores how these AI tools significantly reduce interhospital transfer (IHT) times, enabling faster treatment and better patient outcomes. The case study focuses on a 47-year-old patient with a right parieto-occipital hematoma. Thanks to Viz.ai's advanced AI, the patient was swiftly identified and transferred via the Neuroemergencies Management and Transfer (NEMAT) program. The technology cut the average IHT time from 200 minutes to just 101 minutes in this instance. This accelerated timeline allowed the patient to undergo timely surgical evacuation and achieve substantial neurological recovery within the year. "Viz ICH has revolutionized our approach to identifying and managing ICH patients," said Dr. Christopher Kellner, Director of the Intracerebral Hemorrhage Program at Mount Sinai. "By automating diagnosis and providing real-time alerts to clinical teams, this technology streamlines the entire transfer process, ensuring that patients receive the necessary care without delay." Intracerebral hemorrhage, which affects up to 15% of all stroke patients, is associated with high morbidity and mortality rates. Rapid diagnosis and intervention are critical for effective treatment. Accurate measurement of the hematoma volume is essential to assess the severity of the bleed, monitor its progression, and guide treatment decisions. Traditionally, these measurements were performed manually, a process that is both time-consuming and prone to errors. Viz ICH and Viz ICH Plus, however, integrate seamlessly into the workflow, automating volume measurements and supporting more expeditious and precise care decisions. Beyond reducing transfer time, the AI-powered detection and quantification also enhance clinical workflow efficiency. The technologies enable faster and more accurate hematoma volume estimation compared to manual methods. This benefit is particularly valuable in large, complex hospital systems where specialized ICH care is often concentrated at specific sites. Molly Madziva Taitt, Ph.D., Vice President of Global Clinical Affairs at Viz.ai, emphasized the company's mission: "At Viz.ai, we are dedicated to using AI to eliminate the gaps in stroke care and ensure that every patient receives fast and accurate treatment, regardless of where they initially seek help. This study clearly shows how AI can minimize delays, facilitate early interventions, and ultimately lead to improved patient outcomes in ICH cases." For more information on Viz ICH Plus, visit their website at viz.ai/hyperdensity-measurements. About Viz.ai, Inc. Viz.ai is a pioneering company that employs AI algorithms and machine learning to accelerate diagnosis and care in over 1,700 hospitals and health systems across the United States and Europe. The Viz.ai One® platform is an intelligent care coordination solution designed to detect suspected diseases, inform critical decisions at the point of care, and optimize care pathways to enhance patient outcomes. Supported by extensive clinical evidence, Viz.ai One provides significant benefits to patients, healthcare providers, and medical device companies. To learn more, visit Viz.ai. More News From Viz.ai, Inc. Viz.ai continues to lead the way in leveraging AI to transform healthcare, offering solutions that improve diagnostic accuracy and streamline clinical processes. Stay tuned for more updates and advancements from this innovative company.